Abstract
Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have